Deucravacitinib (BMS-986165) (C09-0862-038)

InformationDeucravacitinib (BMS-986165) Deucravacitinib (BMS-986165) is a highly potent and selective allosteric inhibitor of Tyk2 with a Ki value of 0.02 nM for binding to the Tyk2 pseudokinase domain. It is highly selective against a panel of 265 kinases and pseudokinases.TargetsTyk2 (Cell-free assay) 0.02 nMIn vitroBMS-986165 is highly differentiated from all other reported JAK/TYK2 inhibitors due to its ability to achieve an unprecedented level of selectivity for TYK2, especially over JAK1, JAK2, and JAK3.In vivoBMS-986165 has been identified as a highly potent and selective allosteric TYK2 inhibitor having excellent PK properties across species with minimal profiling liabilities and is orally efficacious with dose-dependent activity in a murine disease model of psoriasis. Significant activity has also been observed with 11 in other murine autoimmune disease models of colitis and lupus.Cell Research(from reference)Cell lines：CD3+ T-cells, CD161+ CD3+ T-cells, TF-1 cells, mononuclear cells, platelets Concentrations：0 - 10 μM. Specification: 0.98 Molecular Formula: C20H19D3N8O3 Molecular Weight: 425.46 PubChem CID: 134821691 Isomeric SMILES: [2H]C([2H])([2H])NC(=O)C1=NN=C(C=C1NC2=CC=CC(=C2OC)C3=NN(C=N3)C)NC(=O)C4CC4